Improving Decision-Making for Medications in Rheumatoid Arthritis (Text Version)

Slide presentation from the AHRQ 2011 conference.

On September 19, 2011, Ed Yelin made this presentation at the 2011 Annual Conference. Select to access the PowerPoint® presentation (345 KB). Plugin Software Help.


Slide 1

Improving Decision-Making for Medications in Rheumatoid Arthritis

Improving Decision-Making for Medications in Rheumatoid Arthritis (RA)

Edward Yelin, Ph.D.,
Jennifer Barton, M.D.
Laura Trupin, M.P.H.
Gina Evans-Young

University of California, San Francisco (UCSF)

Slide 2

Background to Project-1

Background to Project-1

  • Evidence-based consensus that early treatment with disease-modifying agents (DMARDs), including new biological agents, results in improved outcomes for RA.
  • Project 2008-2010 to describe prevalence of problems in patient-physician communication in RA for vulnerable populations:
    • Conducted at two UCSF sites: public hospital and tertiary hospital clinics.
    • Observed clinically meaningful discordance between patients and physicians in assessment of disease severity.
    • Found clinically and statistically significant differences in shared decision-making about treatments, disease severity, and functional status by race/ethnicity, language, and immigration status.

Slide 3

Background to Project-2

Background to Project-2

  • Disparities in outcomes differed by site:
    • Pronounced disparities at tertiary care setting, but almost none at public hospital clinic setting.
  • Suggests the hypothesis that select features of public hospital clinic reduce disparities in communication, decisionmaking, treatments, and ultimately outcomes:
    • Features include ....
      • Translation services.
      • Clinicians and staff with experience in multicultural care (including language).
      • Clinicians and staff with experience in "working the system" for access to contemporary medications.

Slide 4

Examining Room as One Source of Disparity (But Not Only Source)

Examining Room as One Source of Disparity (But Not Only Source)

Image: Figure 1, shows the Study Model flowchart.

Slide 5

Background to Project-3

Background to Project-3

  • Accumulating evidence that public sector clinical settings may improve treatment choices for vulnerable populations:
    • Investigators found that quality of care for systemic lupus erythematosus may be substantially better in public managed care organizations.
  • Trial designed to test one aspect of public hospital clinic's service mix for RA: communication about medication choices:
    • Three arms:
      • Existing RA Medication summary guide (from AHRQ).
      • New RA Medication summary guide modified in consultation with members of vulnerable populations and rheumatologists.
      • New RA medication summary guide plus decision aid tool to be used in clinical encounters.

Slide 6

Background to Project-4

Background to Project-4

  • Outcomes assessed in trial....
    • Primary:
      • Knowledge about medications.
      • Decisional conflict about medications.
    • Secondary:
      • Assessment of interpersonal processes of care ("objective") and satisfaction with providers ("subjective").
      • Treatment uptake for disease-modifying agents and side-effect profile.
      • Disease activity and functional status at six months.
  • Trial began last week with goal of 75 persons with RA in each arm.
  • Criteria for enrollment:
    • Member of vulnerable population based on one or more of following:
      • Low health literacy, immigrant, elder, non-English speaker, non-white.
    • Currently taking at least one disease-modifying agent.
    • Currently active disease.

Slide 7

RA Treatment Trial and Framework for Evaluating iAdapt Projects

RA Treatment Trial and Framework for Evaluating iAdapt Projects

  • Reach:
    • All participants will be in targeted population (but we will monitor participation rate by category of vulnerability).
    • Trial is really designed to see if health delivery system can overcome vulnerabilities brought to the ambulatory setting.
  • Effectiveness:
    • Secondary goal of trial is to assess impact of summary guide and decision aid on outcomes (outcomes are multi-dimensional).
  • Adoption, implementation:
    • Will achieve adoption by FIAT given trial.
    • Implementation snafus will be closely observed despite trial.
  • Maintenance:
    • Will measure outcomes at six months (but not primary outcomes of knowledge of and decisional conflict about medications).

Slide 8

Can You Bottle the Essence of a Clinic Focused on Vulnerable Populations?

Can You Bottle the Essence of a Clinic Focused on Vulnerable Populations?

  • Prior project treated the two UCSF clinics as black boxes and found that one clinic was able to reduce disparities in access and outcomes.
  • Current project "breaks into" the black box to test whether ability to communicate effectively about treatment choices is key element in improving outcomes in vulnerable populations.
  • We will monitor implementation, but basically assume that we are operating in a lab, that is a clinic with an unnaturally small number of snafus dealt with in advance.
  • RA may be good test of attempt to improve process of care since role of timely use of DMARDs has been proven effective and made the basis of treatment guidelines.
Current as of March 2012
Internet Citation: Improving Decision-Making for Medications in Rheumatoid Arthritis (Text Version). March 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/news/events/conference/2011/yelin/index.html